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Effects of omega-3 fatty acids on complement-mediated glomerular
epithelial cell injury. To define the mechanisms by which fish oil protects
rats with passive Heymann nephritis (PHN) from proteinuria in vivo, we
investigated whether omega-3 fatty acid substitution of glomerular epithe-
hal cells (GEC) in culture alters their susceptibility or response to
complement-mediated sublethal injury. The results show that GECs can
be cultured under conditions that effectively incorporate omega-3 or
omega-6 fatty acids into membrane phospholipids without causing toxicity.
Under these conditions, sublethal injury with anti-Fx1A and C5b-9
stimulated a 6.6-fold increase in TxA2 production by GECs substituted
with arachidonic acid (AA, omega-6) but no increase was detected in
eicosapentaenoic acid (EPA, omega-3) substituted cells. Sublethal cell
membrane injury was of equal severity in both groups as measured by the
release of preloaded biscarboxyethyl carboxyfluorescein and by the trans-
epithelial flux of albumin. In addition, omega-3 and omega-6 fatty acid
substituted cells showed similar increases in diacylglycerol mass in re-
sponse to sublethal injury by C5b-9, suggesting that omega-3 incorporation
did not limit phospholipid (PL) hydrolysis by PLC. From this we can
conclude that the protective effect of fish oil in PHN does not appear to
result from the preservation of GEC integrity but is likely related to
changes in the production of lipid mediators.
The passive Heymann nephritis (PHN) model of membranous
nephropathy in rats is characterized by antibody-mediated and
complement-dependent glomerular epithelial cell injury [1] ac-
companied by a substantial increase in glomerular eicosanoid
production [2—4]. Several [4—8], though not all [2], studies using
pharmacological blockers further indicated that the stimulated
release of eicosanoids by injured glomeruli contributes to the
magnitude of proteinuria in both active and passive Heymann
nephritis. Related observations have been made in glomerular
epithelial cells grown in culture [9]. Sublethal quantities of the
complement membrane attack complex, C5b-9, activate phospho-
lipases C and A2, which initiates a cascade of cell signaling events
[10, 11] and stimulates the production of eicosanoids and other
inflammatory mediators [12—15]. Moreover, certain of these
events, particularly calcium mobilization and activation of protein
kinase C, appear to contribute to the ability of these [16] and
other cells [17] to withstand an otherwise lethal attack by C5b-9.
Based on the foregoing observations we reasoned that substi-
tuting omega-3 fatty acids into cell membrane phospholipids by
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feeding rats a fish oil enriched diet might ameliorate injury in
PHN by altering the profile of glomerular eicosanoids. Indeed, we
found that a fish oil enriched diet abrogated the level of protein-
uria in rats with PHN and markedly reduced the glomerular
production of dienoic eicosanoids [3]. While these results sug-
gested that the beneficial effects of fish oil in PHN are due to a
reduction in TxA2, and production instead of TxA3, they did not
discount the possibility of a direct effect of omega-3 fatty acids on
the susceptibility or response of GECs to complement-mediated
injury.
In the studies reported here we aimed to establish if omega-3
fatty acid substitution protects GECs from sublethal complement-
mediated injury and, if not, determine whether it alters their
response to such injury. Our results show that the major omega-3
fatty acid, eicosapentaenoic acid (EPA), can be effectively incor-
porated into GEC membrane phosphohipids but it does not alter
the susceptibility of the cells to C5b-9. On the other hand,
substitution of EPA (omega-3) for arachidonic acid (omega-6)
markedly reduces the output of dienoic eicosanoids, particularly
TxA2.
Methods
Rat glomerular epithelial cell culture
Passaged rat GECs from a continuous cell line [9] were used for
all experiments. The epithelial nature of these cells was estab-
lished by their polygonal shape and cobblestone appearance at
confluence, cytotoxic susceptibility to low doses of aminonucleo-
side of puromycin, positive immunofluorescence staining for
cytokeratin, and presence of junctional complexes on electron
microscopy [9]. Additionally, these cells secrete collagen and
laminin in a polarized fashion [18], express complement regula-
tory proteins [19], a31 integrins [20, 21], and antigens that are
present on rat GECs and that contribute to subepithelial immune
deposits in vivo [22]. Therefore, these cells have several charac-
teristics displayed by visceral GECs in vivo. Experiments were
completed with cells between passages 19 and 30.
The cells were grown in standard Ki medium [13] or KI
supplemented with fatty acids. Standard Ki medium consists of
47% Dulbecco's modified Eagle's Medium (GIBCO, Grand Is-
land, NY, USA), 47% Ham's FlO (GIBCO), 4.9% Nuserum
(Collaborative Research, Bedford, MA, USA) and 0.1% hormone
mix. The hormone mix contains hydrocortisone (18 ng/ml), insulin
(5 .tg/ml), prostaglandin E1 (25 nglml), selenium (Na2SeO2, 1.7
nglml), transferrin (5 mg/mI) and 3,5,3'-triiodothyronine (T3,
0.325 ng/ml) (Sigma Chemical Company, St Louis, MO, USA).
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Fatty acid supplementation of GECs in culture
To determine if GECs could thrive in fatty acid supplemented
medium and to establish the maximum amount of fatty acid that
could be tolerated, they were grown in Ki medium or KI
supplemented with 5 to 30 sM of linoleic acid (LA, 18:2, omega-
6), arachidonic acid (AA, 20:4, omega-6), EPA (20:5, omega-3),
oleic acid (OA, 18:1, omega-9), or palmitic acid (PA, 16:0)
(NuChek Prep, Elysian, MN, USA) for 24, 48 or 72 hours.
Viability of GECs plated with KI medium containing 10%
decomplemented calf serum (K1/CS) or K1/CS supplemented
with 50 /LM AA or EPA was also measured. The fatty acids were
added to the medium in the form of the sodium salt. Stock fatty
acid was added to 1 N NaOH in a glass test tube and quickly dried
under nitrogen. Warm water was added to dissolve the fatty acid
sodium salt and the solution was immediately transferred into the
Ki medium. Fresh medium was prepared in this way for all
experiments. GEC viability was determined by the uptake of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MiT)
in collagen coated 96-well culture dishes (Costar, Cambridge,
MA, USA) as previously described [20, 23]. MTT, a tetrazolium
salt, is taken up and converted to a visible reaction product in the
mitochoridria of live cells. Optical density was measured on an
ELISA plate reader (model MR 5000; Dynatech, Chantilly, VA,
USA) using a test wavelength of 570 nm and a reference
wavelength of 630 nm. MIT uptake was determined from the OD
570/630 ratio, which is linearly related to the number of viable
cells [201.
Incorporation of supplemented fatty acids into the four major
classes of GEC membrane phospholipids: phosphatidylserine
(PS), phosphatidylinositol (PT), phosphatidyicholine (PC) and
phosphatidylethanolamine (PE) was determined isotopically by
thin layer chromatography (TLC) as previously described [101.
GECs were grown to confluence in 35 mm wells (6 wells per plate;
Costar) in the presence of 3H-EPA or '4C-LA (New England
Nuclear, Boston, MA, USA) at a concentration of 1 sCi/2.5 ml of
medium. The radiolabeled fatty acids were added at the time of
plating together with 15 /SM LA or EPA supplemented KI
medium. After 24, 48 and 72 hours, the medium was replaced with
0.5 ml of ice-cold methanol and the cells were scraped into a glass
tube containing the supernatant and acidified with formic acid
(final concentration 0.2%, vol/vol). The lipids were extracted into
0.75 ml of chloroform-methanol (1:1.2) followed by 0.75 ml of
chloroform. The solution was vortexed, centrifuged at 3,000 rpm
for 10 minutes, the upper aqueous phase aspirated, and the
remaining lower lipid phase evaporated under nitrogen. The
organic phase was redissolved in a small amount of chloroform
and spotted onto heat-inactivated LK5-DF silica gel TLC plates
(Whatman, Clifton, NJ, USA) alongside appropriate phospho-
lipid standards. The phospholipid classes were separated with a
chloroform-methanol-acetic acid-water (50:37.5:3.5:2) solvent.
The lipid bands were visualized with iodine vapor and those of
interest were scraped separately into scintillation fluid and
counted in a f3-scintillation counter. The counts in the four
phospholipid fractions were expressed as a percentage of the total
radioactivity in each sample.
The uptake of individual fatty acids into GEC phospholipids
was further analyzed by gas chromatography. GECs were grown in
Ki medium alone, KI medium containing 15 ,LLM of LA, EPA or
AA, or Ki medium supplemented with 10% decomplemented calf
serum (as a source of AA) or 10% decomplemented calf serum
enriched in EPA. To enrich with EPA, the calf serum was
supplemented with 100 ILM EPA in 0.1% fatty acid free bovine
serum albumin and dialyzed for 48 hours against Hanks' balanced
salt solution containing the same supplement. After growth for 48
hours in these media, cellular lipids were extracted as described
above and resolved by TLC using a solvent system of hexane:
ethyl-ether:glacial acetic acid (70:30:1). The phospholipid fraction
was identified with co-chromatographed standards, scraped, and
eluted from the gel with a 1:1 chloroform:methanol solvent. The
fatty acids were transmethylated using BF3ICHIOH (Supelco,
Bellafonte, PA, USA) [24]. The fatty acid methyl esters were
separated on a 100 meter silica capillary column (RTX 2330;
Restek, Bellefonte, PA, USA) packed with 90% biscyanopropyl
and 10% phenylcyanopropyl using a 5890 Hewlett Packard sepa-
ration system (Hewlett Packard Co., Avondale, PA, USA)
equipped with a flame ionization detector (Dr. E. Siguel, Nutri-
tion Unit, Boston University Medical Center, Boston, MA, USA).
The fatty acid peaks were identified according to authentic
standards (NuChek Prep) and quantification was performed using
peak integration software (Justice Innovation, CA, USA). The
results are expressed as a percentage of the total fatty acids in
each sample.
Antibody and complement components
The complement fixing nephritogenic yl subclass of sheep
anti-FxIA IgG was used to sensitize the cells to complement. The
non-complement fixing y2 subclass of anti-FxIA or nonimmune
sheep IgG were used as controls. The yl and y2 subclasses of
sheep anti-FxIA IgG were separated and purified by ion exchange
chromatography as described [25]. Freshly donated normal hu-
man serum (NHS) was used as the source of complement.
Previous studies have shown that sublethal injury induced in this
way is entirely dependent upon assembly of C5b-9, the membrane
attack complex of complement [9]. Heat-inactivated human serum
(HIS, 56°C for 30 mm) served as the negative control.
Measurement of complement-mediated sublethal cytotoxicity
Sublethal injury to GECs sensitized with anti-Fx1A and ex-
posed to complement was assessed by the release of cell-incorpo-
rated biscarboxyethyl carboxyfluorescein (BCECF, molecular
weight 820; Molecular Probes, Eugene, OR, USA) as previously
described [9]. GECs were grown for 24 or 48 hours in 24 well
plates (Costar) containing KI medium alone or KI medium
supplemented with 15 p. fatty acid or 10% AA- or EPA-enriched
calf serum as described above. Fatty acid supplements included
AA, LA, EPA, PA, or OA. After 24 or 48 hours, the cells were
washed with PBS and simultaneously loaded with 8 sM BCECF
and sensitized with 2 mg/ml of yl anti-Fx1A for 40 minutes at
22°C on a microtiter plate shaker. Control cells were incubated
with the same concentration of the non-complement fixing anti-
FxIA y2 subclass or normal sheep IgG. After washing with PBS,
experimental GECs were exposed to 5% NHS and control GECs
to HIS for 40 minutes at 37°C. The supernatants were collected
into individual microcentrifuge tubes. Aliquots of supernatant
were also saved for thromboxane analysis (see below). The cells
were washed with PBS and then lysed with mellitin (Sigma), 200
jig/mI in PBS, for 30 minutes at 37°C. The lysates were collected
into individual tubes and, together with the supernatants, centri-
fuged for five minutes at 5,000 rpm. BCECF released into the
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supernatants was quantified spectrofluorimetrically (Perkin-
Elmer Co.) using an excitation wavelength of 506 nm and an
emission wavelength of 530 nm. Specific BCECF release was
calculated from the equation (E — S)/(M — S) >< 100, where E is
experimental release, S is spontaneous release and M is maximum
release (E plus melittin-induced release). Spontaneous release of
BCECF was determined using supernatants from GECs incu-
bated with PBS prior to lysis with mellitin.
Measurement of transepithelial albumin flux
Substituted and non-substituted cells were grown to confluence
on 12 mm diameter collagen precoated polycarbonate filters (pore
size 3.0 tim) suspended in multiwell plates (Costar). The optimal
plating density and time taken for the cells to grow to confluence
was defined in preliminary experiments. At confluence, rat albu-
min (50 .rg/ml) was added to the lower chamber and basal
albumin flux was measured by sampling from the upper chamber
after 24 hours. 'yl anti-Fx1A and NHS or y2 anti-Fx1A and HIS
were then added to the lower chamber and samples were collected
from the upper chamber at various time points over a further 24
hours period. The concentration of albumin in medium collected
from both upper and lower chambers was measured by sandwich
ELISA using Microtiter plates (Falcon, Becton-Dickinson, Ox-
nard, CA, USA) precoated with 100 l of 20 j.rg/ml sheep anti-rat
albumin (Cappel Research Products, Durham, NC, USA) [18].
Samples were diluted 1 X 106 and the reaction was developed with
hiotin-conjugated anti-rat albumin (4 jig/mI) (Cappel) and an
avidin-peroxidase detection system (Sigma). Rat albumin (Sig-
ma), diluted in the same buffer, was used as the standard.
Thromboxane production by GECs in response to complement-
mediated injury
The concentration of TxB2, the stable metabolite of TxA2, in
GEC-conditioned medium was measured by radioimmunoassay.
The supernatants of GECs grown to confluence in Ki medium or
in Ki supplemented with 15 j.LM AA or EPA and exposed to yl
anti-Fx1A and NHS (experimental) or to the same concentrations
of normal sheep IgG or Y2 anti-Fx1A and HIS (control) for one
hour were used for this assay (see above). In addition, to assess
the ability of EPA to compete with AA, confluent non-substituted
cells in multiwell plates were exposed to yl anti-Fx1A (2 mglml)
and normal human serum for one hour at 37°C in the presence of
a fixed concentration of AA (30 jIM) and an increasing concen-
tration of EPA (0 to 240 jIM). Medium was then collected and
assayed for TxB2.
A 100 pA aliquot of GEC-conditioned medium or TxB2 stan-
dard was incubated with 100 j.tl specific antiserum (Sigma) and
100 pA 3H TxB2 in buffer (1.21 g/liter Tris, 6.16 g/liter NaC1, pH
7.4) for one hour at 4°C. Unbound ligand was precipitated by
addition of dextran-coated charcoal and the radioactivity in the
supernatant was measured in a 13 liquid scintillation counter. The
concentration of TxB2 was calculated from a standard curve. The
cross reactivity of other arachidonate metabolites with anti-TxB2
at 50% displacement was as follows: <0.1%: PGA, PGA2, PGB1,
PGB2, PGD2, PGE1, PGE2, PGF1, 6-keto-PGF1,, 13,14-dihydro-
15-keto-PGE2, 13,14-dihydro-15-keto-PGF2,,; 0.5%: PGF2,. Cross
reactivity with the trienoic thromboxane class (TxB3) was not
determined by the manufacturer and was therefore, unknown.
LA EPA Ki
(18:2) (20:5) None
Media conditions: Fatty acid supplemented or K1 alone
Fig. 1. GEC growth and viability in the presence of fatty acid supplements.
Cells were grown in the presence of 15 /.LM linoleic (LA, omega-6) or
eicosapentaenoic (EPA, omega-3) acid or standard, unsupplemented low
serum medium (Ki). The number of viable cells was measured in parallel
plates after 24 (ii), 48 (2) and 72 (•) hours by the uptake of MTT
(Methods). Values are mean SEM (N = 6/condition at each time point).
Diacylglycerol production by GECs in response to complement-
mediated injury
GECs were plated in 6 well plates (Costar) for 48 hours in Ki
medium or Ki supplemented with the sodium salt of either 15 jIM
AA, EPA, LA, OA or PA. After 48 hours, experimental and
control GECs were sensitized with 2 mg/mI anti-Fx1A for 40
minutes at 22°C as described above. This was followed by an
additional 2 to 10 minutes incubation of experimental GECs with
5% NHS and control cells with 5% HIS. The final incubation was
terminated with the addition of 750 pA ice-cold methanol. GEC
lipids were then extracted as described earlier. Diacylglycerol
(DAG) mass was determined in each sample with an assay that
utilizes sn-1,2-DAG kinase extracted from Escherichia coli (Lipi-
dcx, Westfield, NJ, USA) according to the method developed by
Preiss [26]. The assay employed 32P-ATP as substrate and the
mass of sn-1,2-DAG was determined by measuring the radioactive
phosphatidic acid product, separated from the total lipid pool by
TLC, and identified with a cochromatographed phosphatidic acid
standard (Sigma). DAG mass was calculated from a curve of
DAG standards measured in the same assay. The results are
expressed as nanograms of DAG per well and as percent increase
of DAG production according to the equation: (mean experimen-
tal)/(mean control) X 100.
Statistical analyses
Analyses were done with StatViewlM 512+ (Brainpower, Inc.,
Calabasas, CA, USA). Analysis of variance (ANOVA) was used
to test for differences between multiple groups, and differences
between groups over time was tested by two-way ANOVA for
repeated measures. A two-tailed t-test was used comparisons
1.5
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Table 1. Incorporation of radiolabeled fatty acids into GEC phospholipids
[3H or ['4 fatty acid incorporated into phospholipids
percentage of total radioactivity
EPA LA EPA LA EPA LA
24 hours" 48 hoursa 72 hoursa
P1
PS
PC
PE
7.0 0.00
3.0 0.00
8.5 0.35
70.0 0.00
9.5 0.75
6.8 0.54
25.0 0.65
40.0 2.90
6.3 0.65 7.0 0.50
3.5 0.25 4.0 0.50
7.5 0.25 22.0 0.89
73.5 0.43 49.5 2.27
12.0 0.00
3.0 0.00
10.5 0.35
67.0 0.71
6.3 0.65
6.0 0.00
20.0 0.21
49.0 5.00
Abbreviations are: EPA, [3H1-eicosapentaenoic acid; LA, [CI-linoleic acid; P1, phosphatidylinositol; PS, phosphatidylserine; PC, phosphatidyicho-
line; PE, phosphatidylethanolamine.
"Time in culture in the presence of EPA or LA
between two groups. A P value of < 0.05 was considered
significant.
Results
Fatly acid substitution of rat GECs
As illustrated in Figure 1 for LA and EPA, the viability and
proliferative ability of GECs were unaffected by adding omega-6
or omega-3 polyunsaturated fatty acids (PUFAs) to the growth
medium for periods up to 72 hours at concentrations up to 15 /.LM.
The viability and growth of cells grown in fatty acid concentrations
of 18 IIM and 30 LM for up to 48 hours were no different than in
cells grown in standard Ki medium; thereafter, however, both the
omega-6 and omega-3 PIJFAs moderately inhibited the increase
in MTT-positive cells indicating some cell attrition and/or a
reduced rate of proliferation (data not shown). On phase contrast
microscopy, cells exposed to concentrations of fatty acid greater
than 15 j.tM were more vacuolated than KI controls or cells
exposed to the lower concentrations. Cell survival was not further
improved by adding the antioxidant cs-tocopherol (25 I.LM) or
delipidated bovine serum albumin (1%) to the medium (results
not shown). Therefore, in subsequent long-term studies (>24 hr),
fatty acid concentrations were limited to 15 ).tM and the medium
was not further modified. These conditions were also found to be
appropriate for various other poly- and monounsaturated fatty
acids including arachidonic, palmitic and oleic acids.
Addition of tracer amounts of tritiated fatty acids and analysis
of membrane phospholipids by thin layer chromatography indi-
cated that isotopic equilibrium was achieved within 24 hours. The
distribution of EPA and LA incorporated into the major classes of
phospholipids is shown in Table 1. From these analyses, the
labeled omega-6 fatty acids derived from LA were preferentially
incorporated into phosphatidylcholine and phosphatidylethanol-
amine whereas the labeled omega-3 fatty acids from EPA were
mainly located in phosphatidylethanolamine Table 1. Uptake into
phosphatidylinositol was a small but significant fraction of the
total incorporation and was similar for the two fatty acids.
Gas chromatography of phospholipids from GECs grown in the
presence of 15 /.LM AA or EPA showed significant incorporation of
the respective fatty acids as compared to cells grown in standard
Ki medium (Fig. 2). Although LA-substituted cells had signifi-
cantly more LA than cells grown in KI medium alone they did not
show an increase in AA, which suggests that elongation of LA to
AA (the major omega-6 fatty acid in the sn-2 position of phos-
pholipids) is relatively inefficient in these cells. Therefore, several
subsequent studies were conducted with AA instead of LA. The
gas chromatographic analysis further revealed a baseline fatty acid
profile that suggests essential fatty acid deficiency in cells grown in
standard Ki medium containing approximately 2.5% fetal bovine
serum (triene:tetraene ratio 2.35 0.019) and that this profile is
not substantially improved by the addition of 15 kM AA (triene:
tetraene ratio 0.506 0.018), LA (triene:tetraene ratio 1.515
0.137) or EPA (2.03 0.151). Therefore, to confirm that our
results were not attributable to essential fatty acid deficiency,
further studies were conducted in which the deficiency was
corrected by growing the cells in Ki medium containing 10% calf
serum enriched in AA or EPA. This increased the amount of AA
and EPA in GEC phospholipids and improved the triene:tetraene
ratio to <0.2. The gas chromatographic analysis of these cells is
also shown in Figure 2.
Effects of fatly acid substitution on GEC susceptibility to
complement-mediated injury
Figure 3 illustrates one of several experiments conducted to
determine if the fatty acid composition of membrane phospholip-
ids influenced the susceptibility of GECs to sublethal comple-
ment-mediated injury as measured by release of the fluoroprobe,
BCECF. Exposure to complement-fixing yl anti-Fx1A and fresh
human serum as the source of complement produced substantial
release of BCECF as compared to control cells exposed to y2
anti-Fx1A and heat-inactivated serum; however, the level of
release was not significantly different in cells substituted with
various fatty acids than in unsubstituted cells. In particular, EPA
substitution did not render the cells more resistant to injury. AA
substitution induced slightly more basal leakage of BCECF in
control cells but this did not make them more sensitive to
complement-mediated injury. Supernatants from this experiment
were subsequently analyzed for thromboxane B2 release (see
below). Similar results were obtained in other experiments in
which EPA-substituted cells were compared to cells substituted
with LA, palmitic acid and oleic acid (data not shown).
To ensure that a significant effect of omega-3 fatty acid
substitution was not masked by an underlying deficiency in
essential fatty acids, similar experiments were conducted with
GECs in which the deficiency had been corrected. As before, the
results showed no difference between AA- and EPA-substituted
and urisubstituted cells (Fig. 4). Similarly, in GECs exposed to a
lethal dose of complement (10% fresh human serum), cell viabil-
ity as measured by MTT uptake was not significantly improved by
EPA substitution (data not shown).
The functional effects of complement-mediated GEC injury
were further quantified by measuring transepithelial albumin flux.
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Fig. 2. Gas chromatographic analysis of GEC
membrane phospholipids after fatty acid
supplementation. Cells were grown for 48 hours15 in Ki medium alone, Ki medium containing 15
/LM of arachidonic (AA, omega-6), linoleic (LA,
omega-6) or eicosapentaenoic (EPA, omega-3)
acid, or Ki medium supplemented with 10%
10 decomplemented calf serum (AA!CS) or 10%
. decomplemented calf serum enriched with EPA5 (EPA/CS). The lightly hatched bars (0)
represent omega-6 and the darkly hatched (r3)
5 bars represent omega-3 fatty acids. The black
bars (•) are the ratio of fatty acids (20:3:20:4)
and are barely visible in the AA/CS and EPA!
CS lanes (values > 0.2 are indicative of
0 essential fatty acid deficiency). Values are the
average of 2 to 3 determinations. The axis on
the left represents the sum of all omega-6 or
omega-3 fatty acids expressed as a percentage
of total fatty acids. The axis on the right
indicates the triene:tetraene ratio.
Fig. 3. Effect of fatty acid substitution on sublethal complement-mediated
cytotoxicily. GECs were grown for 48 hours in Ki medium alone or KI
medium containing 15 M of AA or EPA. They were then loaded with 8
j.rM BCECF and sensitized with 2 mg/mI of yl anti-FxIA (experimental) or
non-complement fixing y2 anti-FxIA for 40 minutes at 22°C. Experimental
GECs (L::) were exposed to 5% fresh serum and control GECs (•) to
heat-inactivated serum for 40 minutes at 37°C. Specific BCECF release,
expressed as a percentage of total releasable BCECF, is significantly
different between experimentals and controls within each group (P <
0.001) but there is no significant difference between groups (ANOVA).
Values are mean SEM (N = 6/group).
Fig. 4. Effect of restoring GEC fatty acids with .4A or EPA on sublethal
complement-mediated cytotoxicily. GECs were grown for 48 hours in Ki
medium containing 10% decomplemented calf serum alone (K1/CS) or
enriched in AA (AA/CS) or EPA (EPA/CS). At the time of plating, 50 j.sM
AA or EPA was added to AA/CS or EPA/CS, respectively. The cells were
then loaded with BCECF and exposed to antibody and complement and
studied as described in Figure 3. BCECF release is significantly different
between experimentals () and controls (•) within each group (P <
0.001) and is slightly but significantly lower in K1/CS controls (P < 0.01)
but there is no significant difference between experimental groups
(ANOVA). Values are mean SEM (N = 3/group).
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Media conditions
GECs grown to confluence on collagen-coated permeable sup-
ports provide an effective barrier to the passage of macromole-
cules. This barrier was rapidly destroyed by sublethal injury by
Effects of fatly acid substitution on the response of GECs to
sublethal complement-mediated injuly
complement (Fig. 5), however, the rate of albumin leakage was Increased release of eicosanoids is an established sublethal
not different in omega-3 or omega-6 substituted cells than in cytotoxic effect of complement. This was verified in these studies
unsubstituted cells. by a higher level of thromboxane B2 production by GECs
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Fig. 5. Effect of fatty acid substitution on transepithelial flux of albumin.
GECs were grown to confluence on collagen coated polycarbonate filters
suspended in multiwell plates in the presence of Ki medium alone or KI
medium containing 15 jrM of LA or EPA. At confluence, rat albumin (50
sg/ml) was added to the lower chamber and basal albumin flux was
measured by sampling from the upper chamber after 24 hours. yl
anti-Fx1A and fresh serum (experimental) or y2 anti-Fx1A and heat-
inactivated serum (control) were then added to the lower chamber and
samples were collected from the upper chamber at various time points
over a further 24 hour period. No significant increase in the flux of
albumin was observed in control cells. Increased flux occurred in all
experimental groups (P < 0.001) but was not significantly different
between the groups (ANOVA). Values are mean of four separate
experiments each using three replicate wells (SaM < 8%). Symbols are:() KI control; () KI experimental; (0) LA experimental; (A) EPA
experimental.
sensitized with yl anti-Fx1A and exposed to complement than
cells exposed to normal sheep serum and heat inactivated com-
plement (Fig. 6). This difference was seen in all medium condi-
tions, presumably reflecting the residual AA in membrane phos-
pholipids, but was most evident in cells enriched with AA (Fig. 6).
AA-enriched cells demonstrated a 6.6-fold greater level of throm-
boxane B2 production than cells in standard Ki medium after
stimulation with complement. On the other hand, despite the
equivalent level of injury in EPA- and AA-substituted cells
exposed to antibody and complement, there was substantially less
thromboxane B2 produced by EPA-substituted cells (Fig. 6).
Furthermore, EPA was able to competitively inhibit thrombox-
ane B2 production by complement stimulated GECs even in the
presence of AA. In this experiment, medium recovered from
non-substituted cells exposed for one hour to yl anti-Fx1A and
complement in the presence of 30 mM AA contained 3.75 0.32
ng/ml thromboxane B2. Addition of EPA at the time of stimula-
tion led to a concentration dependent decrease (65% at 120 mM)
in thromboxane B2 production by injured cells but did not
completely block the production of this eicosanoid (Fig. 7). These
results suggest that EPA competes effectively with AA as a
substrate for cyclooxygenase.
Using trace labeling technicjues, we have previously shown that
there is increased diacylglycerol (DAG) production when GEC
membrane phospholipids are hydrolyzed in response to sublethal
injury by complement [10]. In these studies we measured the total
amount of DAG released in response to complement because one
cannot be certain that trace-labeled fatty acids of different classes
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Media conditions: Fatty acid supplemented or K1 alone
Fig. 6. Effect of fatty acid substitution on complement-mediated thrombox-
one B2 production. The experimental conditions are described in the
legend to Figure 3 except that TxB2 was measured in the supernatants
after one hour of incubation. TxB2 production was increased in experi-
mental cells (ti) under all media conditions as compared to controls (•;
P < 0.05), but was significantly greater in AA-substituted than in Ki or
EPA-substituted experimental cells (P < 0.005, ANOVA). Values are
mean SD (N = 4/group) from a representative experiment.
are equally incorporated into the sn-2 position of membrane
phospholipids. We confirmed, in several experiments, that anti-
Fx1A and complement stimulate an increase in DAG mass but we
also found an effect of serum alone when incubation was extended
for 10 minutes or more (data no shown). Therefore, in the
experiment shown in Figure 8, DAG production by GECs sensi-
tized with anti-FxIA was measured after two minutes of exposure
to complement or heat-inactivated serum. DAG levels were
higher in the experimental GECs than in the respective controls
regardless of whether the cells were grown in standard Ki
medium or KI supplemented with 15 ,ILM EPA or LA. The percent
increase of DAG production in injured GECs over control GECs
grown in Ki was 161%. The increases observed with omega-6 and
omega-3 supplemented cells were 209% (LA) and 183% (EPA),
respectively. Similar increases were seen with oleic (256%) and
palmitic (204%) acid substituted cells (data not shown), however
the mass of DAG released after complement-mediated injury did
not differ between cells substituted with any of the various fatty
acids.
Discussion
These experiments were specifically designed to determine if
omega-3 fatty acid substitution of GECs in culture alters their
susceptibility or response to complement-mediated sublethal in-
jury. Our results show that omega-3 or omega-6 fatty acids can be
effectively incorporated into membrane phospholipids of cultured
GECs without causing toxicity. Under these conditions, sublethal
injury with anti-Fx1A and C5b-9 stimulated a 6.6-fold increase in
TxA2 production by GECs substituted with AA (omega-6). On the
other hand, no increase was detected in EPA (omega-3) substi-
tuted cells despite a similar degree of cell membrane injury as
measured by the release of preloaded BCECF (a marker of
sublethal cytotoxicity) and by the transepithelial flux of albumin.
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EPA concentration, /IM
Fig. 7. Dose-response effect of EPA on TxB2 production by complement-
stimulated AA-supplemented GECs. Confluent non-substituted cells were
exposed to yl anti-Fx1A (2 mg/mI) and normal human serum for one hour
at 37°C in the presence of a fixed concentration of AA (30 M) and an
increasing concentration of EPA (0 to 240 LM). The medium was then
assayed for TxB2 A significant dose-related inhibition of TxB2 production
was observed at EPA concentrations up to 120 M (P < 0.05, ANOVA).
Values are mean so (N 4/dose).
In addition, omega-3 and omega-6 fatty acid substituted cells
showed similar increases in diacylglycerol mass in response to
sublethal injury by C5b-9, indicating that omega-3 incorporation
did not limit phospholipid hydrolysis by PLC. From these findings
we conclude that the protective effect of fish oil in PHN does not
appear to result from the preservation of GEC integrity, but may
be related to the changes in lipid mediators such as TxA2, a potent
vasoconstrictor eicosanoid that has been implicated in the patho-
genesis of proteinuria [27].
In attempting to understand the mechanisms by which fish oil
ameliorates proteinuria in experimental membranous nephropa-
thy [3, 28], we were faced with two possibilities. The first would
implicate a hemodynamic, pro-inflammatory or cytopathic effect
of lipid mediators. It is well established that glomeruli isolated
from such rats produce high levels of eicosanoids [2—4, 281. It is
particularly relevant to our present studies that high levels of
TxA2 are produced in response to complement-mediated injury
[2] and are suppressed by fish oil [3]. We also found that selective
blockade of thromboxane synthase suppressed the magnitude of
proteinuria in an isolated perfused kidney model of PHN [5].
PLA2-induced hydrolysis of EPA-substituted membrane phospho-
lipids leads to production of trienoic prostanoids (for example
PGI3, PGE1 and TxA1) and pentaenoic leukotrienes (for example
LTBS) instead of dienoic prostanoids (PGI2, PGE2 and TxA2) and
tetraenoic leukotrienes (LTB4). TxA3 and LTB5 are weak ago-
fists. Consequently, TxA3 is much less effective in stimulating
platelet aggregation and vasoconstriction than TxA2, and LTB5 is
a less potent leukocyte chemotaxin and stimulant of leukocyte-
endothelial adhesion than LTB4 [28]. TxA3 is also a competitive
Media conditions: Fatty acid substituted or Ki alone
Fig. 8. Effect of fatly acid substitution on complement-mediated diacylglyc-
erol (DAG) production. GECs were grown for 48 hours in Ki medium
alone or Ki medium containing 15 M of LA or EPA. They were then
sensitized with 2 mg/ml of yl anti-Fx1A (experimental) or non-comple-
ment fixing y2 anti-Fx1A (control) for 40 minutes at 22°C. Experimental
GECs were exposed to 5% fresh serum and control GECs to heat-
inactivated serum for two minutes at 37°C. DAG mass was then measured
in lipid extracts of the methanol-lysed cells by the DAG kinase assay
(Methods). DAG mass was significantly greater in experimental cells than
in controls (P < 0.001) but did not differ between experimental groups
(ANOVA). Values are mean SEM (N = 3 to 4/group).
inhibitor of TxA2 [29], and LTA5 competes for LTA4-hydrolase
[30], the rate-limiting enzyme for the conversion of LTA4 to
LTB4, LTC4 and LTD4 [31]. Therefore, the benefits of fish oil
might have been due to changes in the production of lipid
mediators in response to complement-mediated cell injury.
The second possibility, and the one tested in these studies,
predicts that omega-3 fatty acids afford direct cytoprotection
against the attack by C5b-9. This concept is given credence by our
studies of complement-mediated sublethal GEC injury in vitro,
which disclosed an intracellular signaling cascade that involves
phospholipid hydrolysis and results in the production of 1P3, DAG
and eicosanoids, as well as the release and influx of calcium [10,
11]. In addition, in vitro studies have demonstrated that incorpo-
ration of omega-3 fatty acids into vascular smooth muscle inositol
phospholipids [32], reduces agonist-induced phosphoinositide
turnover, 1P3 generation and calcium transients [33, 34], suggest-
ing that similar mechanisms may be at work in injured glomeruli.
Therefore, by analogy to these findings, we reasoned that similarly
treated GECs might exhibit reduced phospholipid hydrolysis and
less membrane damage in response to complement. It is impor-
tant to note, however, that some of the events activated by
complement in GECs appear to contribute to their ability to
withstand an attack by complement [161, perhaps by stimulating
membrane vesiculation and shedding of C5b-9 complexes [35—38].
Therefore, we were aware that omega-3 fatty acids might aggra-
vate injury by inhibiting these protective mechanisms or by
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increasing GEC susceptibility to potential membrane damaging
effects of oxidants or high levels of calcium [14, 39].
In support of a direct cytoprotective action, there is evidence
that certain effects of fish oils cannot be readily attributed to their
ability to modify lipid mediators. For example, fish oils or purified
omega-3 fatty acids inhibit the proliferation of precancerous cells
[40] and the oncogenic transformation of cultured fibroblasts [41].
They reduce cytokine and growth factor production by mononu-
clear (42] and endothelial [431 cells, and suppress the expression
of leukocyte adhesion molecules on activated endothelial cells
[44]. They also correct the hyperlipidemia of nephrotic rats [45]
and abolish calcium-dependent ventricular fibrillation in cultured
cardiac myocytes [46].
Our results are informative in several respects. In contrast to
the observations in vascular smooth muscle cells [32—34], we
found that altering the composition of membrane phospholipids
had no appreciable effect on phospholipid hydrolysis (as mea-
sured by DAG release) in response to complement. In particular,
omega-3 fatty acid substituted GECs released as much DAG as
cells substituted with omega-6, monounsaturated and saturated
fatty acids after stimulation with C5b-9. Not surprisingly, the
stimulated release from unsupplemented cells was slightly lower
than the other groups. Furthermore, sensitive functional assays of
cell membrane and epithelial integrity did not demonstrate pro-
tection by omega-3 fatty acids. On the other hand, there was no
evidence that polyunsaturated fatty acid supplementation aggra-
vated injury. These findings are consistent with our in vivo
observations, in which podocyte effacement and condensation of
the actin cytoskeleton were seen to be similar in fish oil and
safflower oil fed rats with PHN despite a reduction in proteinuria
with fish oil [3].
Presubstitution with EPA markedly inhibited complement-
stimulated TxB2 release by GECs, consistent with the docu-
mented activation of PLA2 by C5b-9 [11] and the ability of EPA
released from the sn-2 position of membrane phospholipids to
competitively inhibit the interaction of AA and cyclooxygenase.
Moreover, addition of EPA at the time of injury suppressed TxB2
release in a dose-dependent fashion. This is likely due, at least in
part, to a direct action of free EPA that is rapidly translocated
across the lipid bilayer into the cells where it competes with AA
being released from membrane phospholipids (especially phos-
phatidyicholine) by complement-activated PLA2 [15]. Therefore,
the profound reduction in glomerular TxB2 production observed
in fish oil fed PHN rats [3] is likely due to the combined effects of
phospholipid-associated and free omega-3 fatty acids. Although
there may have been a concomitant rise in TxA3, this cannot be
ascertained without a specific assay.
We should also point out that these and our previous in vivo
studies do not exclude the possibility that the benefits of fish oil in
PHN are due, in part, to an effect on other lipid or non-lipid
mediators. For example, it has been shown that glomerular LTB4
production is significantly increased soon after anti-Fx1A injec-
tion and at the onset of complement-dependent proteinuria in
PHN [41 Further studies with pharmacological inhibitors demon-
strated that LTB4 contributes to the magnitude of proteinuria,
and LTD4 to the glomerular hemodynamic changes that charac-
terize the autologous phase of PHN, and that the primary origin
of these products of the 5-lipoxygenase pathway appears to be a
small but significant infiltrate of mononuclear cells [8]. However,
our own studies have consistently failed to reveal a role for
leukocytes in the pathogenesis of GEC injury and proteinuria in
the heterologous phase of PHN [1, 47], and there is no evidence
as yet that GECs are capable of synthesizing leukotrienes [31].
Therefore, in studying the primary events responsible for this
model of injury, namely complement-mediated GEC damage, we
have focused on the eicosanoids produced by GECs in vivo and in
vitro.
In conclusion, these studies indicate that podocytes injured by
complement are the likely source of thromboxane released by
glomeruli isolated from rats with PHN and that fish oil amelio-
rates proteinuria by switching eicosanoids to the omega-3 series,
rather than by protecting their structural integrity.
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